07, June 2017

Notice of Annual General Meeting on 30 June 2017 at 10.30am

Notice of Annual General Meeting on 30 June 2017 at 10.30amInvestor presentation to follow at 11.30amVenue: Sky Light City, 50 Basinghall Sreet, London, EC2ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"...

Click here for more details

06, June 2017

Final Results Announcement for the twelve months ended 31 December 2016

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2016 (the "P...

Click here for more details

24, May 2017

Notification of full year results -1 June 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its full year results for the year ended 31 December 2016 on Thursday 1 June 2017.

...

Click here for more details

17, May 2017

Update on Lupuzor™ Pivotal Phase III Study

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for...

Click here for more details

21, March 2017

Notification of Major Interest by Legal & General

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc (“L&G”...

Click here for more details

21, March 2017

TR1 Notification of Major Interest

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has today received a TR-1 by Aviva plc (“Aviva”). Aviva’s holding in ImmuPharma is now confirmed at a total of 10,2...

Click here for more details

10, March 2017

Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that further to the announcement made earlier today entitled “Accelerated Bookbuild for the Issue of Equity”, the ac...

Click here for more details

10, March 2017

Accelerated Bookbuild for the Issue of Equity

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce a proposed placing, raising a minimum of £3 million (before expenses), via the issue of new ordinary shares of 10p each (&...

Click here for more details

25, January 2017

Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide further details of patient participation following confirmation (as announced on 22 December 2016) that the Company had successfu...

Click here for more details

24, January 2017

Change of Adviser

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with immediate effect....

Click here for more details